Actively Recruiting
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
Led by University of Iowa · Updated on 2025-12-15
24
Participants Needed
2
Research Sites
111 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The use of electronic nicotine delivery systems, or e-cigarettes - colloquially referred to as "vaping" - in the United States has increased exponentially since their introduction to the US market in 2007. Prevalence of ever and current e-cigarette use is highest among teenagers and young adults with 16-28% of this population having reported vaping. While the majority of e-cigarette users are current tobacco smokers, 32.5% of current e-cigarette users are never- or former-smokers, representing a growing population of young adults who exclusively vape. While e-cigarettes have been marketed as a safer alternative to tobacco cigarettes, clinical studies examining these claims are limited. Cardiovascular disease (CVD) is the primary cause of premature death among tobacco cigarette smokers and reductions in vascular endothelial function, a significant predictor of future CVD, are detectible in otherwise healthy young adults who smoke. Despite the explosion in e-cigarette use among young adults, the health effects - especially the effects on mechanisms of vascular function - of these devices remain relatively unexplored. The purpose of this study is to directly asses the mechanistic role of inflammation in this dysfunction.
CONDITIONS
Official Title
Role of Inflammation in Vascular Phenotype Associated With E-cigarette Use
Who Can Participate
Eligibility Criteria
You may qualify if you...
- 18 to 24 years of age
- No history of e-cigarette use (control) OR current use with at least 6 months history of e-cigarette use (chronic use)
You will not qualify if you...
- Current or past use of tobacco cigarettes
- Use of stimulant drugs
- Presence of skin diseases
- Cardiovascular disease
- Diagnosed or suspected liver or metabolic diseases including diabetes
- Use of statins or other cholesterol-lowering medications
- Use of antihypertensive medications
- Current pregnancy or breastfeeding
- Blood pressure greater than or equal to 140 mmHg systolic and/or 90 mmHg diastolic
- Allergy to materials used during the experiment
- Known allergies to salsalate or other study drugs
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 2 locations
1
Iowa Bioscience Innovation Facility
Iowa City, Iowa, United States, 52242
Actively Recruiting
2
University of Iowa
Iowa City, Iowa, United States, 52242
Actively Recruiting
Research Team
A
Anna Stanhewicz, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
BASIC_SCIENCE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here